Results 121 to 130 of about 87,670 (247)

Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis. [PDF]

open access: yesJ Lipid Res, 2023
Moreau F   +8 more
europepmc   +1 more source

Plasma Exosome Metabolomics Reveal Stage‐Specific Alterations in Elderly Women With Premetabolic and Metabolic Syndrome

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Shared differential metabolites identified across the three sample groups. (A) Venn diagram of differential metabolites between the two comparison groups; Based on the detected levels of these overlapping differential metabolites, (B) d‐Arabitol, (C) Triclosan, (D) Iloprost, (E) Tetracosanoic acid, and (F) Omeprazole sulfone. Box plots were constructed
Mengtao Qian   +4 more
wiley   +1 more source

Living Microbial Drugs

open access: yesChemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik   +3 more
wiley   +1 more source

Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis. [PDF]

open access: yesFront Pharmacol, 2022
Shen B   +9 more
europepmc   +1 more source

Effect of Late Second to Early Third Trimester of Pregnancy on the Activity of Renal Organic Anion Transporters (OAT1 and OAT3): A Biomarker Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pregnant individuals take drugs throughout pregnancy and many of these drugs (e.g., antivirals, antibiotics) are eliminated by renal organic anion transporters (OAT) 1 and OAT3. In vivo studies with OAT1/3 substrate drugs suggest that pregnancy increases renal OAT1/3 activities by 1.5‐ to 1.8‐fold.
Aarzoo Thakur   +4 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu   +6 more
wiley   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo   +4 more
wiley   +1 more source

Clinical and genetic features of congenital bile acid synthesis defect with a novel mutation in AKR1D1 gene sequencing: Case reports. [PDF]

open access: yesMedicine (Baltimore), 2022
Pham AN   +14 more
europepmc   +1 more source

Phase I Metabolism of Novel Phencyclidine Derivative 3‐Cl‐PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post‐Mortem Case

open access: yesDrug Testing and Analysis, EarlyView.
A fatal 3‐chloro‐phencyclidine (3‐Cl‐PCP) intoxication was investigated by analyzing postmortem samples and a pooled human liver microsomes assay. Tentative metabolite identification was performed by liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS). Seven phase I metabolites were identified.
Johannes Kutzler   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy